Towards the end of the first year of the RadioVal project, SHINE 2Europe and the remaining partners were welcomed in Barcelona on 19-20 June for a plenary meeting of the consortium. The Universitat de Barcelona, leader of the consortium, was the host, welcoming the rest of the consortium.

RadioVal is a Horizon Europe-funded project that aims to validate an artificial intelligence solution to support breast cancer treatment decisions. This is the most common type of cancer among women worldwide; although it can affect men, the incidence rate is much lower. According to the World Health Organisation it is estimated that more than 2 million new cases of breast cancer occur each year, making it one of the leading causes of death among women. It is estimated that around 685,000 women die each year from breast cancer.

Partners reflected on how the first year of this large multi-centre and multi-disciplinary project, focused on validating a tool for targeted response in breast cancer patients requiring neoadjuvant chemotherapy, has gone in eight clinical centres in Europe, South America, North America and Eurasia.

SHINE is leading the dialogue work with doctors, patients, artificial intelligence (AI) researchers, ethics and legal officers and other experts to understand the exact needs of all stakeholders. It is also engaging a multidisciplinary group of international actors, in addition to the consortium partners, to extract as much input as possible to achieve a more reliable AI tool for decision-making.